Oestrogen Receptor Positive Breast Cancer Metastasis to Bone: Inhibition by Targeting the Bone Microenvironment in Vivo

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2015 Nov 21

PMID 26585891

Citations 23

Authors

I Holen

M Walker

F Nutter

A Fowles

C A Evans

C L Eaton

P D Ottewell

Affiliations

Soon will be listed here.

Abstract

Clinical trials have shown that adjuvant Zoledronic acid (ZOL) reduces the development of bone metastases irrespective of ER status. However, post-menopausal patients show anti-tumour benefit with ZOL whereas pre-menopausal patients do not. Here we have developed in vivo models of spontaneous ER+ve breast cancer metastasis to bone and investigated the effects of ZOL and oestrogen on tumour cell dissemination and growth. ER+ve (MCF7, T47D) or ER-ve (MDA-MB-231) cells were administered by inter-mammary or inter-cardiac injection into female nude mice ± estradiol. Mice were administered saline or 100 μg/kg ZOL weekly. Tumour growth, dissemination of tumour cells in blood, bone and bone turnover were monitored by luciferase imaging, histology, flow cytometry, two-photon microscopy, micro-CT and TRAP/P1NP ELISA. Estradiol induced metastasis of ER+ve cells to bone in 80-100 % of animals whereas bone metastases from ER-ve cells were unaffected. Administration of ZOL had no effect on tumour growth in the fat pad but significantly inhibited dissemination of ER+ve tumour cells to bone and frequency of bone metastasis. Estradiol and ZOL increased bone volume via different mechanisms: Estradiol increased activity of bone forming osteoblasts whereas administration of ZOL to estradiol supplemented mice decreased osteoclast activity and returned osteoblast activity to levels comparable to that of saline treated mice. ER-ve cells require increased osteoclast activity to grow in bone whereas ER+ve cells do not. Zol does not affect ER+ve tumour growth in soft tissue, however, inhibition of bone turnover by ZOL reduced dissemination and growth of ER+ve breast cancer cells in bone.

Citing Articles

Radiosynthesis and Preclinical Evaluation of F-Labeled Estradiol Derivatives with Different Lipophilicity for PET Imaging of Breast Cancer.

Friedel A, Prante O, Maschauer S Cancers (Basel). 2024; 16(15).

PMID: 39123367 PMC: 11311842. DOI: 10.3390/cancers16152639.

The progressive trend of modeling and drug screening systems of breast cancer bone metastasis.

Kolahi Azar H, Gharibshahian M, Rostami M, Mansouri V, Sabouri L, Beheshtizadeh N J Biol Eng. 2024; 18(1):14.

PMID: 38317174 PMC: 10845631. DOI: 10.1186/s13036-024-00408-5.

A Novel Metastatic Estrogen Receptor-Expressing Breast Cancer Model with Antiestrogen Responsiveness.

Langsten K, Shi L, Wilson A, Lumia S, Westwood B, Skeen A Cancers (Basel). 2023; 15(24).

PMID: 38136319 PMC: 10742098. DOI: 10.3390/cancers15245773.

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo.

Saleh L, Ottewell P, Brown J, Wood S, Brown N, Wilson C Cancers (Basel). 2023; 15(8).

PMID: 37190140 PMC: 10137281. DOI: 10.3390/cancers15082211.

The genomic regulation of metastatic dormancy.

Gelman I Cancer Metastasis Rev. 2023; 42(1):255-276.

PMID: 36600151 PMC: 10231431. DOI: 10.1007/s10555-022-10076-w.

References

Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P . Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2012; 24(2):398-405. DOI: 10.1093/annonc/mds277. View

Ottewell P, Monkkonen H, Jones M, Lefley D, Coleman R, Holen I . Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008; 100(16):1167-78. DOI: 10.1093/jnci/djn240. View

Green J, Guenther A . The backbone of progress--preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol. 2011; 77 Suppl 1:S3-S12. DOI: 10.1016/S1040-8428(11)70003-8. View

Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K . Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007; 130(5):811-23. DOI: 10.1016/j.cell.2007.07.025. View

Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E . Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014; 15(9):997-1006. DOI: 10.1016/S1470-2045(14)70302-X. View

Ottewell P, Wang N, Brown H, Reeves K, Fowles C, Croucher P . Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res. 2014; 20(11):2922-32. PMC: 4040234. DOI: 10.1158/1078-0432.CCR-13-1246. View

Haider M, Holen I, Dear T, Hunter K, Brown H . Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis. Bone. 2014; 66:240-50. PMC: 4127787. DOI: 10.1016/j.bone.2014.06.023. View

Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P . Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int. 2012; 12(1):48. PMC: 3519531. DOI: 10.1186/1475-2867-12-48. View

Coleman R, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M . Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011; 365(15):1396-405. DOI: 10.1056/NEJMoa1105195. View

10.

Ottewell P, Wang N, Brown H, Fowles C, Croucher P, Eaton C . OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Int J Cancer. 2015; 137(4):968-77. DOI: 10.1002/ijc.29439. View

11.

Ottewell P, Deux B, Monkkonen H, Cross S, Coleman R, Clezardin P . Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008; 14(14):4658-66. DOI: 10.1158/1078-0432.CCR-07-1545. View

12.

Khosla S . Update on estrogens and the skeleton. J Clin Endocrinol Metab. 2010; 95(8):3569-77. PMC: 2913030. DOI: 10.1210/jc.2010-0856. View

13.

Fleming J, Miller T, Meyer M, Ginsburg E, Vonderhaar B . Local regulation of human breast xenograft models. J Cell Physiol. 2010; 224(3):795-806. PMC: 2897719. DOI: 10.1002/jcp.22190. View

14.

Holen I, Whitworth J, Nutter F, Evans A, Brown H, Lefley D . Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo. Breast Cancer Res. 2012; 14(3):R86. PMC: 3446349. DOI: 10.1186/bcr3201. View

15.

Benford H, McGowan N, Helfrich M, Nuttall M, Rogers M . Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001; 28(5):465-73. DOI: 10.1016/s8756-3282(01)00412-4. View

16.

Ottewell P, Brown H, Jones M, Rogers T, Cross S, Brown N . Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast Cancer Res Treat. 2011; 133(2):523-36. DOI: 10.1007/s10549-011-1782-x. View

17.

Miyagawa F, Tanaka Y, Yamashita S, Minato N . Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol. 2001; 166(9):5508-14. DOI: 10.4049/jimmunol.166.9.5508. View

18.

Brown H, Holen I . Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?. Curr Cancer Drug Targets. 2009; 9(7):807-23. DOI: 10.2174/156800909789760339. View

19.

Muinelo-Romay L, Garcia D, Alonso-Alconada L, Vieito M, Carmona M, Martinez N . Zoledronic acid as an antimetastatic agent for different human tumor cell lines. Anticancer Res. 2013; 33(12):5295-300. View

20.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C . Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360(7):679-91. DOI: 10.1056/NEJMoa0806285. View